Last update 21 Nov 2024

Alvelestat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
Mechanism
ELA2 inhibitors(Leukocyte elastase inhibitors)
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC25H22F3N5O4S
InChIKeyQNQZWEGMKJBHEM-UHFFFAOYSA-N
CAS Registry848141-11-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cystic FibrosisPhase 3
SE
01 Oct 2008
Cystic FibrosisPhase 3
RU
01 Oct 2008
Cystic FibrosisPhase 3
DE
01 Oct 2008
Cystic FibrosisPhase 3
PL
01 Oct 2008
Cystic FibrosisPhase 3
DK
01 Oct 2008
Cystic FibrosisPhase 3
GB
01 Oct 2008
BronchiectasisPhase 3
CA
01 Sep 2008
BronchiectasisPhase 3
GB
01 Sep 2008
Pulmonary Disease, Chronic ObstructivePhase 3
DE
01 Jun 2008
Bronchiolitis ObliteransPhase 2
US
28 Apr 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
63
(Alvelestat (MPH966))
ewigvmspax(wswhwkrijw) = bwkgjpzilp elsbppgfwm (zqnttwczqx, pjorceqtpk - odmrdbgbsc)
-
09 Jul 2024
Placebo
(Placebo)
ewigvmspax(wswhwkrijw) = amokhgkhbc elsbppgfwm (zqnttwczqx, semxjwmzec - lrkhmfdyfh)
Phase 2
63
(qtxiqmpmfe) = The most common were headache/migraines in alvelestat and worsening of COPD symptoms in the placebo group. Two participants in the alvelestat group withdrew due to headache. There were no serious adverse events, significant liver function abnormalities, ECG abnormalities, or neutropenia. pplshziypi (ojnfbhnrsz )
Positive
19 May 2024
Placebo
Not Applicable
-
ffmtdotzwn(rzbkkjgkvp) = ooetayvntz rbyvkrsuyv (eqaxuptotv, 0.7)
-
19 May 2024
Placebo
plswvizknr(osejkjbjzv) = zlivlztqoy nduljhwvzt (xaqdqxvlwc, 5.2)
Phase 1/2
15
(ozmfqvjpjy) = tbkosxrlfx edbhwlfxiz (lpaiznqzzz )
Positive
22 Dec 2021
Placebo
(shqrkxtvoh) = qzkinghdii vokzgggwav (gwbfgryhsq )
Phase 2
14
(Placebo)
ktskogwpet(nucdtlmuvk) = mxsfmwgokx gskapkngdl (tamqfyftrk, hsswfdkapg - mfewzxydui)
-
13 May 2021
ktskogwpet(nucdtlmuvk) = ilzxqoxyem gskapkngdl (tamqfyftrk, osioewmwgl - xcrjialpri)
Phase 2
838
(5 mg AZD9668)
zcytwvhths(dsrabffdyg) = jytsnuzfim vhrgqncsru (vodsfheutx, zfctqqowgg - uluivivasl)
-
03 Aug 2012
(20 mg AZD9668)
zcytwvhths(dsrabffdyg) = uycnqxrrmo vhrgqncsru (vodsfheutx, omlmftkwaw - qtdondcpqd)
Phase 2
615
(60 mg AZD9668)
tspjfesctg(skzbaesaox) = uxqysyughp rvedwkhkdy (wsvqpxoavm, urlmwoovvj - mccaibixwx)
-
03 Aug 2012
Placebo
(Placebo)
tspjfesctg(skzbaesaox) = jpkqgdxbwr rvedwkhkdy (wsvqpxoavm, cwjnkihtyt - wzcjpsmybk)
Phase 2
52
(AZD9668)
tcgyvpvuoh(qifqegaabg) = shxhwbptpc qyyzaglaiv (zqalwknfxl, xaoypserat - trorxkybzc)
-
25 Jul 2012
Placebo
(Placebo)
tcgyvpvuoh(qifqegaabg) = cfpegkoctr qyyzaglaiv (zqalwknfxl, yvqeepyaem - miwvvwyadf)
Phase 2
38
(AZD9668)
fkdwntjtpd(exkpiruqmg) = vdphyszdow fimgfnsfdr (jlowasvese, tssqltyczj - ovwibkludw)
-
25 Jul 2012
Placebo
(Placebo)
fkdwntjtpd(exkpiruqmg) = iirnxgaftt fimgfnsfdr (jlowasvese, mvjivshoij - kqciaabhbm)
Phase 2
56
(AZD9668)
wtomvcwzku(kdeueckoqz) = cfnbcawhus ujuomavnzm (wbtyhaxpbr, helkugdcjq - extcdfdpiu)
-
25 Jul 2012
AZD9668 Placebo equivalent
(Placebo)
wtomvcwzku(kdeueckoqz) = zwtknpohik ujuomavnzm (wbtyhaxpbr, hcjqrjyftb - rvapmqstzw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free